<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04197778</url>
  </required_header>
  <id_info>
    <org_study_id>DDO-3055-102</org_study_id>
    <nct_id>NCT04197778</nct_id>
  </id_info>
  <brief_title>Food Effect Study of DDO-3055 Tablets in Healthy Subjects</brief_title>
  <official_title>Food Effect Study of DDO-3055 Tablets in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a randomized , open-label, two-stage crossover food effect study of single doses
      of DDO-3055 tablets in healthy subjects. 14 healthy subjects were randomly divided into
      groups A and B, 7 subjects in each group. Two stage washout period is 6 days.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2019</start_date>
  <completion_date type="Anticipated">April 2020</completion_date>
  <primary_completion_date type="Anticipated">April 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the concentration-time curve (AUC) of DDO-3055</measure>
    <time_frame>up to 2 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum plasma concentration (Cmax) of DDO-3055</measure>
    <time_frame>up to 2 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to maximum observed serum concentration (Tmax) of DDO-3055</measure>
    <time_frame>up to 2 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal elimination half-life (T1/2) of DDO-3055</measure>
    <time_frame>up to 2 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent total clearance of the drug from plasma after oral administration (CL/F) of DDO-3055</measure>
    <time_frame>up to 2 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent volume of distribution after oral administration (V/F) of DDO-3055</measure>
    <time_frame>up to 2 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of endogenous erythropoietin from baseline</measure>
    <time_frame>up to 2 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>up to 9 days</time_frame>
    <description>Use the incidence and severity of adverse events to assess safety and tolerability</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">14</enrollment>
  <condition>Anemia in Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DDO-3055 tablet</intervention_name>
    <description>DDO-3055 tablet, 2 single doses separated by 6 days.</description>
    <arm_group_label>group A</arm_group_label>
    <arm_group_label>group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. Healthy male volunteers, aged 18~45.

          -  2. Body weight ≥ 50 kg, body mass index (BMI) between 18 to 28.

          -  3. Hemoglobin is in the normal range.

          -  4. Signed informed consent.

        Exclusion Criteria:

          -  1. Vital signs, physical examination, laboratory results are abnormal and clinically
             significant.

          -  2. Currently suffering from cardiovascular, liver, kidney, digestive, nervous, blood,
             thyroid or mental diseases.

          -  3. Suspected allergy to the active ingredient or excipient of the experimental drug.

          -  4. Have used erythropoietin within 1 month prior to screening or are currently using
             erythropoietin.

          -  5. Had donated blood or blood transfusion within 3 months prior to screening.

          -  6. Vein blood collection is difficult or physical condition can not afford blood
             collection.

          -  7. Hepatitis b virus surface antigen (HBsAg), hepatitis c virus antibody (HCVAb),
             Syphilis antibody, human immunodeficiency virus antibody (HIVAb)were positive.

          -  8. Average daily smoking ≥5 cigarettes within 3 months before screening; average daily
             intake of alcohol within one week is more than 15g (15g alcohol is equivalent to 450mL
             beer or 150mL wine or 50mL low-alcohol liquor);or 2 days before taking the study drug
             and during the trial take the tobacco and alcohol and caffeinated foods or drinks, and
             have special dietary requirements and cannot follow a uniform diet.

          -  9. 3 months prior to screening involved in any drug or medical device clinical trials,
             or within 5 half-life of drugs before screening.

          -  10. Any health care products, Over-the-counter drugs or prescription drugs that
             affects the absorption, distribution, metabolism and excretion of the experimental
             drug was used within 1 month before the administration.

          -  11. With a history of drug abuse or screening visit/baseline visit urine drug abuse
             screening positive.

          -  12. Subjects who are unwilling to take contraceptives or who are likely to donate
             sperm during the trial and within 30 days after administration; or who do not agree to
             physical contraception during the trial.

          -  13. Other conditions in which the study physician considered the subject not suitable
             for the trial.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jia you hong</last_name>
    <phone>+86-010-88396184</phone>
    <email>fwjyh07@163.com</email>
  </overall_contact>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 3, 2019</study_first_submitted>
  <study_first_submitted_qc>December 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 13, 2019</study_first_posted>
  <last_update_submitted>December 11, 2019</last_update_submitted>
  <last_update_submitted_qc>December 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

